Indoco Remedies’ Baddi Site Gets EU Stamp Of Approval For Europe Bound Pills

The EU GMP clearance is a critical regulatory milestone for any Indian pharmaceutical manufacturer looking to deepen its presence in Europe. For Indoco Remedies, it adds another certified site to its global manufacturing footprint and enhances its credibility with originator companies and generic buyers alike.

What EU GMP Certification Means

EU GMP certification confirms that a facility complies with stringent European standards on quality systems, documentation, validation and manufacturing controls. For Indoco’s Baddi plant, the recognition effectively opens the door for contract development and manufacturing, as well as own label generics, into multiple EU member states.

How The Baddi Site Fits Indoco’s Network

Indoco Remedies operates a network of formulation and API plants catering to domestic and export markets. The Baddi formulation plant III is focused on oral solid dosage forms, which are a key part of the company’s regulated market portfolio. EU GMP status allows Indoco to better utilise this asset for European filings and tenders.

Why This Matters For Growth And Exports

With many global buyers preferring or insisting on EU GMP approved sites, the certification can translate into stronger order flows, higher realisations and longer term supply contracts. It also positions Indoco to participate more meaningfully in Europe’s generic tenders and in-licensing opportunities.

Key Highlights

• Indoco’s formulation plant III at Baddi receives EU GMP certification
• Approval covers oral solid dosage formulations for EU regulated markets
• Certification strengthens Indoco’s export and contract manufacturing prospects
• Enhances company’s credibility and competitiveness in regulated markets

Sources: Indoco Remedies company news, MarketScreener, PharmaNow, Times of India